Kestra Advisory Services LLC Raises Stock Holdings in Novo Nordisk A/S $NVO

Key Points

• Kestra Advisory Services LLC increased its stake in Novo Nordisk A/S by 12.6% during Q1, bringing its total holdings to 156,530 shares valued at approximately $10.87 million.
• Novo Nordisk A/S reported earnings of $0.97 per share for the last quarter, surpassing analysts' estimates of $0.93, with revenues of $11.69 billion.
• The company declared a semi-annual dividend of $0.4119 per share, resulting in a yield of 240.0%, set to be paid on August 26th to investors recorded by August 18th.

Kestra Advisory Services LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 12.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 156,530 shares of the company's stock after buying an additional 17,562 shares during the period. Kestra Advisory Services LLC's holdings in Novo Nordisk A/S were worth $10,869,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of NVO. Copeland Capital Management LLC increased its stake in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth about $27,000. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $29,000. Stone House Investment Management LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth about $30,000. Finally, Disciplina Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock worth $33,000 after purchasing an additional 297 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 2.6%

NVO stock opened at $56.8910 on Friday. The company's 50 day moving average price is $62.57 and its 200 day moving average price is $69.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $139.74. The firm has a market capitalization of $254.02 billion, a price-to-earnings ratio of 15.63, a PEG ratio of 1.98 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is 22.53%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on NVO shares. Barclays reissued an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target on the stock. in a research report on Thursday, July 31st. BNP Paribas raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. Finally, TD Cowen reduced their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, August 19th. Three investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average price target of $81.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.